141 related articles for article (PubMed ID: 11529866)
1. Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells.
Holen I; Drury NL; Hargreaves PG; Croucher PI
Br J Haematol; 2001 Aug; 114(2):414-21. PubMed ID: 11529866
[TBL] [Abstract][Full Text] [Related]
2. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.
Fitzgerald ML; Wang Z; Park PW; Murphy G; Bernfield M
J Cell Biol; 2000 Feb; 148(4):811-24. PubMed ID: 10684261
[TBL] [Abstract][Full Text] [Related]
3. Porphyromonas gingivalis lipopolysaccharide induces shedding of syndecan-1 expressed by gingival epithelial cells.
Andrian E; Grenier D; Rouabhia M
J Cell Physiol; 2005 Jul; 204(1):178-83. PubMed ID: 15648090
[TBL] [Abstract][Full Text] [Related]
4. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation.
Subramanian SV; Fitzgerald ML; Bernfield M
J Biol Chem; 1997 Jun; 272(23):14713-20. PubMed ID: 9169435
[TBL] [Abstract][Full Text] [Related]
5. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration.
Endo K; Takino T; Miyamori H; Kinsen H; Yoshizaki T; Furukawa M; Sato H
J Biol Chem; 2003 Oct; 278(42):40764-70. PubMed ID: 12904296
[TBL] [Abstract][Full Text] [Related]
6. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9.
Kaushal GP; Xiong X; Athota AB; Rozypal TL; Sanderson RD; Kelly T
Br J Haematol; 1999 Feb; 104(2):365-73. PubMed ID: 10050721
[TBL] [Abstract][Full Text] [Related]
8. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor.
Hargreaves PG; Wang F; Antcliff J; Murphy G; Lawry J; Russell RG; Croucher PI
Br J Haematol; 1998 Jun; 101(4):694-702. PubMed ID: 9674743
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.
Børset M; Hjertner O; Yaccoby S; Epstein J; Sanderson RD
Blood; 2000 Oct; 96(7):2528-36. PubMed ID: 11001907
[TBL] [Abstract][Full Text] [Related]
10. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9.
Brule S; Charnaux N; Sutton A; Ledoux D; Chaigneau T; Saffar L; Gattegno L
Glycobiology; 2006 Jun; 16(6):488-501. PubMed ID: 16513763
[TBL] [Abstract][Full Text] [Related]
11. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity.
Seidel C; Børset M; Hjertner O; Cao D; Abildgaard N; Hjorth-Hansen H; Sanderson RD; Waage A; Sundan A
Blood; 2000 Nov; 96(9):3139-46. PubMed ID: 11049995
[TBL] [Abstract][Full Text] [Related]
12. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
Jourdan M; Ferlin M; Legouffe E; Horvathova M; Liautard J; Rossi JF; Wijdenes J; Brochier J; Klein B
Br J Haematol; 1998 Mar; 100(4):637-46. PubMed ID: 9531328
[TBL] [Abstract][Full Text] [Related]
13. Syndecan-1 in B lymphoid malignancies.
Sanderson RD; Børset M
Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737
[TBL] [Abstract][Full Text] [Related]
14. Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site.
Wang Z; Götte M; Bernfield M; Reizes O
Biochemistry; 2005 Sep; 44(37):12355-61. PubMed ID: 16156648
[TBL] [Abstract][Full Text] [Related]
15. [The expression, secretion and regulation of membrane-soluble syndecan-1 in human multiple myeloma cells].
Li X; Lu Z; Klein B
Zhonghua Xue Ye Xue Za Zhi; 2000 Nov; 21(11):572-6. PubMed ID: 11225246
[TBL] [Abstract][Full Text] [Related]
16. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.
Ridley RC; Xiao H; Hata H; Woodliff J; Epstein J; Sanderson RD
Blood; 1993 Feb; 81(3):767-74. PubMed ID: 8427968
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-dependent shedding of syndecan-3, a transmembrane heparan sulfate proteoglycan, in Schwann cells.
Asundi VK; Erdman R; Stahl RC; Carey DJ
J Neurosci Res; 2003 Sep; 73(5):593-602. PubMed ID: 12929127
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.
Dhodapkar MV; Kelly T; Theus A; Athota AB; Barlogie B; Sanderson RD
Br J Haematol; 1997 Nov; 99(2):368-71. PubMed ID: 9375756
[TBL] [Abstract][Full Text] [Related]
19. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1.
Gao G; Plaas A; Thompson VP; Jin S; Zuo F; Sandy JD
J Biol Chem; 2004 Mar; 279(11):10042-51. PubMed ID: 14701864
[TBL] [Abstract][Full Text] [Related]
20. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells.
Ding K; Lopez-Burks M; Sánchez-Duran JA; Korc M; Lander AD
J Cell Biol; 2005 Nov; 171(4):729-38. PubMed ID: 16286510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
